Impact of celiac neurolysis on survival in patients with pancreatic cancer

Larissa L. Fujii-Lau, William R. Bamlet, Jason S. Eldrige, Suresh T Chari, Ferga C. Gleeson, Barham K. Abu Dayyeh, Jonathan E. Clain, Randall K. Pearson, Bret Thomas Petersen, Elizabeth Rajan, Mark Topazian, Santhi Swaroop Vege, Kenneth Ke Ning Wang, Maurits J. Wiersema, Michael J. Levy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Pancreatic cancer (PC) often produces pain that is difficult to control. Celiac neurolysis (CN) is performed with the goal of improving pain control and quality of life while reducing opioid-related side effects. Objective We aimed to evaluate whether CN provides a survival advantage for PC patients. Design Retrospective case-control study. Setting Single tertiary-care referral center. Patients Review of a prospectively maintained database identified patients with unresectable PC who underwent CN over a 12-year period. Each patient was matched to 2 control patients with unresectable PC. Intervention CN, which included both celiac plexus neurolysis (CPN) and celiac ganglia neurolysis (CGN). Main Outcome Measurements Median survival in Kaplan-Meier curves and hazard ratios. Results A total of 417 patients underwent CN and were compared with 840 controls with PC. Baseline characteristics were similar except the CN group had greater weight loss and pain requiring opioids. A mean of 16.6 ± 5.8 mL of alcohol was administered. For patients who underwent CN, the median survival from the time of presentation was shorter compared with controls (193 vs 246 days; hazard ratio 1.32; 95% confidence interval, 1.13-1.54). There was no difference in survival with unilateral or bilateral injection. However, EUS-guided CN was associated with longer survival compared with non-EUS approaches, and those who received CPN had longer survival compared with CGN. Limitations Single center, retrospective. Conclusion Our study suggests that CN is an independent predictor of shortened survival in PC patients. A prospective study is needed to verify the findings and determine whether shortened survival results from CN or from other features such as performance status and tumor-related characteristics. It is also imperative to verify our finding that EUS-guided CN provides a survival advantage over other approaches and whether CPN prolongs survival compared with CGN.

Original languageEnglish (US)
Pages (from-to)46-56.e2
JournalGastrointestinal Endoscopy
Volume82
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Pancreatic Neoplasms
Abdomen
Survival
Celiac Plexus
Sympathetic Ganglia
Tertiary Care Centers
Pain
Opioid Analgesics
Kaplan-Meier Estimate
Case-Control Studies
Weight Loss
Alcohols
Quality of Life
Databases
Prospective Studies
Confidence Intervals
Injections

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

Fujii-Lau, L. L., Bamlet, W. R., Eldrige, J. S., Chari, S. T., Gleeson, F. C., Abu Dayyeh, B. K., ... Levy, M. J. (2015). Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointestinal Endoscopy, 82(1), 46-56.e2. https://doi.org/10.1016/j.gie.2014.12.036

Impact of celiac neurolysis on survival in patients with pancreatic cancer. / Fujii-Lau, Larissa L.; Bamlet, William R.; Eldrige, Jason S.; Chari, Suresh T; Gleeson, Ferga C.; Abu Dayyeh, Barham K.; Clain, Jonathan E.; Pearson, Randall K.; Petersen, Bret Thomas; Rajan, Elizabeth; Topazian, Mark; Vege, Santhi Swaroop; Wang, Kenneth Ke Ning; Wiersema, Maurits J.; Levy, Michael J.

In: Gastrointestinal Endoscopy, Vol. 82, No. 1, 01.07.2015, p. 46-56.e2.

Research output: Contribution to journalArticle

Fujii-Lau, LL, Bamlet, WR, Eldrige, JS, Chari, ST, Gleeson, FC, Abu Dayyeh, BK, Clain, JE, Pearson, RK, Petersen, BT, Rajan, E, Topazian, M, Vege, SS, Wang, KKN, Wiersema, MJ & Levy, MJ 2015, 'Impact of celiac neurolysis on survival in patients with pancreatic cancer', Gastrointestinal Endoscopy, vol. 82, no. 1, pp. 46-56.e2. https://doi.org/10.1016/j.gie.2014.12.036
Fujii-Lau LL, Bamlet WR, Eldrige JS, Chari ST, Gleeson FC, Abu Dayyeh BK et al. Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointestinal Endoscopy. 2015 Jul 1;82(1):46-56.e2. https://doi.org/10.1016/j.gie.2014.12.036
Fujii-Lau, Larissa L. ; Bamlet, William R. ; Eldrige, Jason S. ; Chari, Suresh T ; Gleeson, Ferga C. ; Abu Dayyeh, Barham K. ; Clain, Jonathan E. ; Pearson, Randall K. ; Petersen, Bret Thomas ; Rajan, Elizabeth ; Topazian, Mark ; Vege, Santhi Swaroop ; Wang, Kenneth Ke Ning ; Wiersema, Maurits J. ; Levy, Michael J. / Impact of celiac neurolysis on survival in patients with pancreatic cancer. In: Gastrointestinal Endoscopy. 2015 ; Vol. 82, No. 1. pp. 46-56.e2.
@article{bb4f59dce30348cba5be3c0dd208198b,
title = "Impact of celiac neurolysis on survival in patients with pancreatic cancer",
abstract = "Background Pancreatic cancer (PC) often produces pain that is difficult to control. Celiac neurolysis (CN) is performed with the goal of improving pain control and quality of life while reducing opioid-related side effects. Objective We aimed to evaluate whether CN provides a survival advantage for PC patients. Design Retrospective case-control study. Setting Single tertiary-care referral center. Patients Review of a prospectively maintained database identified patients with unresectable PC who underwent CN over a 12-year period. Each patient was matched to 2 control patients with unresectable PC. Intervention CN, which included both celiac plexus neurolysis (CPN) and celiac ganglia neurolysis (CGN). Main Outcome Measurements Median survival in Kaplan-Meier curves and hazard ratios. Results A total of 417 patients underwent CN and were compared with 840 controls with PC. Baseline characteristics were similar except the CN group had greater weight loss and pain requiring opioids. A mean of 16.6 ± 5.8 mL of alcohol was administered. For patients who underwent CN, the median survival from the time of presentation was shorter compared with controls (193 vs 246 days; hazard ratio 1.32; 95{\%} confidence interval, 1.13-1.54). There was no difference in survival with unilateral or bilateral injection. However, EUS-guided CN was associated with longer survival compared with non-EUS approaches, and those who received CPN had longer survival compared with CGN. Limitations Single center, retrospective. Conclusion Our study suggests that CN is an independent predictor of shortened survival in PC patients. A prospective study is needed to verify the findings and determine whether shortened survival results from CN or from other features such as performance status and tumor-related characteristics. It is also imperative to verify our finding that EUS-guided CN provides a survival advantage over other approaches and whether CPN prolongs survival compared with CGN.",
author = "Fujii-Lau, {Larissa L.} and Bamlet, {William R.} and Eldrige, {Jason S.} and Chari, {Suresh T} and Gleeson, {Ferga C.} and {Abu Dayyeh}, {Barham K.} and Clain, {Jonathan E.} and Pearson, {Randall K.} and Petersen, {Bret Thomas} and Elizabeth Rajan and Mark Topazian and Vege, {Santhi Swaroop} and Wang, {Kenneth Ke Ning} and Wiersema, {Maurits J.} and Levy, {Michael J.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.gie.2014.12.036",
language = "English (US)",
volume = "82",
pages = "46--56.e2",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of celiac neurolysis on survival in patients with pancreatic cancer

AU - Fujii-Lau, Larissa L.

AU - Bamlet, William R.

AU - Eldrige, Jason S.

AU - Chari, Suresh T

AU - Gleeson, Ferga C.

AU - Abu Dayyeh, Barham K.

AU - Clain, Jonathan E.

AU - Pearson, Randall K.

AU - Petersen, Bret Thomas

AU - Rajan, Elizabeth

AU - Topazian, Mark

AU - Vege, Santhi Swaroop

AU - Wang, Kenneth Ke Ning

AU - Wiersema, Maurits J.

AU - Levy, Michael J.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background Pancreatic cancer (PC) often produces pain that is difficult to control. Celiac neurolysis (CN) is performed with the goal of improving pain control and quality of life while reducing opioid-related side effects. Objective We aimed to evaluate whether CN provides a survival advantage for PC patients. Design Retrospective case-control study. Setting Single tertiary-care referral center. Patients Review of a prospectively maintained database identified patients with unresectable PC who underwent CN over a 12-year period. Each patient was matched to 2 control patients with unresectable PC. Intervention CN, which included both celiac plexus neurolysis (CPN) and celiac ganglia neurolysis (CGN). Main Outcome Measurements Median survival in Kaplan-Meier curves and hazard ratios. Results A total of 417 patients underwent CN and were compared with 840 controls with PC. Baseline characteristics were similar except the CN group had greater weight loss and pain requiring opioids. A mean of 16.6 ± 5.8 mL of alcohol was administered. For patients who underwent CN, the median survival from the time of presentation was shorter compared with controls (193 vs 246 days; hazard ratio 1.32; 95% confidence interval, 1.13-1.54). There was no difference in survival with unilateral or bilateral injection. However, EUS-guided CN was associated with longer survival compared with non-EUS approaches, and those who received CPN had longer survival compared with CGN. Limitations Single center, retrospective. Conclusion Our study suggests that CN is an independent predictor of shortened survival in PC patients. A prospective study is needed to verify the findings and determine whether shortened survival results from CN or from other features such as performance status and tumor-related characteristics. It is also imperative to verify our finding that EUS-guided CN provides a survival advantage over other approaches and whether CPN prolongs survival compared with CGN.

AB - Background Pancreatic cancer (PC) often produces pain that is difficult to control. Celiac neurolysis (CN) is performed with the goal of improving pain control and quality of life while reducing opioid-related side effects. Objective We aimed to evaluate whether CN provides a survival advantage for PC patients. Design Retrospective case-control study. Setting Single tertiary-care referral center. Patients Review of a prospectively maintained database identified patients with unresectable PC who underwent CN over a 12-year period. Each patient was matched to 2 control patients with unresectable PC. Intervention CN, which included both celiac plexus neurolysis (CPN) and celiac ganglia neurolysis (CGN). Main Outcome Measurements Median survival in Kaplan-Meier curves and hazard ratios. Results A total of 417 patients underwent CN and were compared with 840 controls with PC. Baseline characteristics were similar except the CN group had greater weight loss and pain requiring opioids. A mean of 16.6 ± 5.8 mL of alcohol was administered. For patients who underwent CN, the median survival from the time of presentation was shorter compared with controls (193 vs 246 days; hazard ratio 1.32; 95% confidence interval, 1.13-1.54). There was no difference in survival with unilateral or bilateral injection. However, EUS-guided CN was associated with longer survival compared with non-EUS approaches, and those who received CPN had longer survival compared with CGN. Limitations Single center, retrospective. Conclusion Our study suggests that CN is an independent predictor of shortened survival in PC patients. A prospective study is needed to verify the findings and determine whether shortened survival results from CN or from other features such as performance status and tumor-related characteristics. It is also imperative to verify our finding that EUS-guided CN provides a survival advantage over other approaches and whether CPN prolongs survival compared with CGN.

UR - http://www.scopus.com/inward/record.url?scp=84930892621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930892621&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2014.12.036

DO - 10.1016/j.gie.2014.12.036

M3 - Article

C2 - 25800661

AN - SCOPUS:84930892621

VL - 82

SP - 46-56.e2

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 1

ER -